Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Chromatin immunoprecipitation (ChIP) is an antibody-based approach that is frequently utilized in chromatin biology and epigenetics. The challenge in experimental variability by unpredictable nature of usable input amounts from samples and undefined antibody titer in ChIP reaction still remains to be addressed. Here, we introduce a simple and quick method to quantify chromatin inputs and demonstrate its utility for normalizing antibody amounts to the optimal titer in individual ChIP reactions. For a proof of concept, we utilized ChIP-seq validated antibodies against the key enhancer mark, acetylation of histone H3 on lysine 27 (H3K27ac), in the experiments. The results indicate that the titration-based normalization of antibody amounts improves assay outcomes including the consistency among samples both within and across experiments for a broad range of input amounts.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074837 | PMC |
| http://dx.doi.org/10.1186/s12864-023-09253-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Titration-WB: A methodology for accurate quantitative protein determination overcoming reproducibility errors.
PLoS One
June 2025
Cardio Metabolic Unit, Department of Medicine Huddinge, and Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Western blotting (WB) is a cornerstone technique for protein detection and quantification in molecular biology. However, its semi-quantitative nature, reliance on housekeeping protein normalization, and susceptibility to technical variability often undermine data accuracy and reproducibility. To address these limitations, we introduce titration-based Western blotting (t-WB), as innovative quantitative approach that uses serial dilutions of protein samples to generate regression curves for precise protein quantification.
View Article and Find Full Text PDFModel-Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor-Induced Osteomalacia.
Clin Pharmacol Ther
December 2024
Kyowa Kirin Inc., Princeton, New Jersey, USA.
Article Synopsis
- Burosumab is approved to treat hypophosphatemia caused by persistent tumor-induced osteomalacia, utilizing a data-informed drug development method to assess its pharmacokinetics and dosing for both adults and children.
- The study combined data from both tumor-induced osteomalacia and X-linked hypophosphatemia to refine understanding of drug behavior, using simulations to propose effective dosing recommendations that can achieve normal phosphate levels with minimal risk of hyperphosphatemia.
- Findings suggest dosing for pediatric patients at 0.3 and 0.4 mg/kg every two weeks, and for adults at 0.3 and 0.5 mg/kg every four weeks, can lead
Titration-based normalization of antibody amount improves consistency of ChIP-seq experiments.
BMC Genomics
April 2023
Epigenomics Development Laboratory, Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Stabile Building 12-04, 200 First Street SW, Rochester, MN, USA.
Chromatin immunoprecipitation (ChIP) is an antibody-based approach that is frequently utilized in chromatin biology and epigenetics. The challenge in experimental variability by unpredictable nature of usable input amounts from samples and undefined antibody titer in ChIP reaction still remains to be addressed. Here, we introduce a simple and quick method to quantify chromatin inputs and demonstrate its utility for normalizing antibody amounts to the optimal titer in individual ChIP reactions.
View Article and Find Full Text PDFBackground: The prevalence of hyperthyroidism is very common in the United States (approximately 1.2%) with Graves' Disease (GD) being the most common non-iatrogenic cause. The limited number of endocrinologists and their concentration in larger cities means that primary care providers (PCPs) must treat a large number of these patients.
View Article and Find Full Text PDFMulti-Omics Analysis of Glioblastoma Cells' Sensitivity to Oncolytic Viruses.
Cancers (Basel)
October 2021
V. L. Talrose Institute for Energy Problems of Chemical Physics, N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.
Oncolytic viruses have gained momentum in the last decades as a promising tool for cancer treatment. Despite the progress, only a fraction of patients show a positive response to viral therapy. One of the key variable factors contributing to therapy outcomes is interferon-dependent antiviral mechanisms in tumor cells.
View Article and Find Full Text PDF